# PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

> **NCT06175832** · PHASE4 · RECRUITING · sponsor: **University Hospital, Ghent** · enrollment: 60 (estimated)

## Conditions studied

- Ovarian Stimulation
- Quality of Life
- Preimplantation Genetic Testing
- Fertility Preservation

## Interventions

- **DRUG:** Elonva®
- **DRUG:** Puregon®
- **DRUG:** Orgalutran®
- **DRUG:** Gonapeptyl®
- **DRUG:** Cerazette®

## Key facts

- **NCT ID:** NCT06175832
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- Organon

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175832, "PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06175832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*